homefeedbacksupportlog on 2-Dec-2008 
  Search
 
   
 
  Browse
ALL OF MEDICINE

Hematology
Anemias & Hypocellular Marrow Disorders
Bleeding & Coagulation Disorders
Hematologic Transplantation & Transfusion
Hematopoietic Stem Cells
Leukemia & Proliferative Disorders of Hematic Cells
Lymphomas & Myelomas
Non-hematopoietic Stem Cells
Pediatric Hematology
Related Sections
Perioperative Hemostasis & Transfusion Medicine

profile subject selected for My F1000 Medicine

Browse > Hematology > Lymphomas & Myelomas
Current Top 10 by F1000 Factor / All Time Top 10 by F1000 Factor / Most viewed
(from all journals) / Most viewed
(from specialty journals) / Hidden jewels		Page 1 of 8. Select Page: 1 2 3 4 5 6 7 8 >>
Display 10 / 20 / 50 papers per page

printer friendly 
to email [Help]

Recommended
F1000 Factor 3.0

Confirmation
 Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.
Palumbo A, Bringhen S, …, Cavo M, Boccadoro M
Blood 2008 Oct 15 112(8):3107-14 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Arati Rao
Evaluated 26 Nov 2008

Recommended
F1000 Factor 3.0

Tech Advance
 Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.
Morschhauser F, Radford J, …, Kuhlmann J, Hagenbeek A
J Clin Oncol 2008 Nov 10 26(32):5156-64 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Nicolas Mounier
Evaluated 21 Nov 2008

Must Read
F1000 Factor 6.0

Confirmation
 Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study.
Salles G, Mounier N, …, Xerri L, Foussard C
Blood 2008 Sep 17 [abstract on PubMed] [related articles] [full text]
Selected by | Armando López-Guillermo
Evaluated 20 Nov 2008

Recommended
F1000 Factor 3.0

Confirmation
New Finding
 Long-term effects of high-dose chemotherapy and radiation for relapsed and refractory Hodgkin's lymphoma.
Goodman KA, Riedel E, …, Moskowitz CH, Yahalom J
J Clin Oncol 2008 Nov 10 26(32):5240-7 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Andreas Engert with Nicole Skoetz
Evaluated 12 Nov 2008

Must Read
F1000 Factor 4.8

New Finding
Tech Advance
 Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH, Lossos IS, …, Zeldis JB, Habermann TM
J Clin Oncol 2008 Oct 20 26(30):4952-7 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Asher Chanan-Khan with Sikander Ailawadhi / Allessandro Gianni with Michele Magni
First evaluation 7 Nov 2008 | Latest evaluation 19 Nov 2008

Must Read
F1000 Factor 4.8

Hypothesis
New Finding
 Seeding and propagation of untransformed mouse mammary cells in the lung.
Podsypanina K, Du YC, …, Hambardzumyan D, Varmus H
Science 2008 Sep 26 321(5897):1841-4 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Larry Suva / Christos Sotiriou with Michail Ignatiadis
First evaluation 7 Nov 2008 | Latest evaluation 11 Nov 2008


Recommended
F1000 Factor 3.0

Hypothesis
 Multiparameter flow cytometry remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Paiva B, Vidriales MB, …, Orfao A, San Miguel JF
Blood 2008 Jul 31 [abstract on PubMed] [related articles] [full text]
Selected by | Xavier Leleu with C Willekens
Evaluated 28 Oct 2008

Recommended
F1000 Factor 3.0

Confirmation
 Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma.
Elstrom RL, Leonard JP, Coleman M, Brown RK
Ann Oncol 2008 Oct 19(10):1770-3 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Michael Williams
Evaluated 20 Oct 2008

Recommended
F1000 Factor 3.0

Confirmation
 International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.
Armitage J, Vose J, Weisenburger D
J Clin Oncol 2008 Sep 1 26(25):4124-30 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Nicolas Mounier with Thomas Cluzeau
Evaluated 20 Oct 2008

Recommended
F1000 Factor 3.0

New Finding
 A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
Musto P, Petrucci MT, …, Palumbo A, GIMEMA (Italian Group for Adult Hematologic Diseases)/Multiple Myeloma Working Party and the Italian Myeloma Network
Cancer 2008 Oct 1 113(7):1588-95 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Xavier Leleu with J Gay
Evaluated 15 Oct 2008


top of pagePage 1 of 8. Select Page: 1 2 3 4 5 6 7 8 >>
Display 10 / 20 / 50 papers per page

© 2008 Medicine Reports Ltd unless otherwise stated. < info@f1000.com >   Terms and conditions   Legal info